Dr. Pathak and associates from Kaiser Permanente, Los Angeles published an article in the June 2007 issue of the Journal of Urology, basing the frequency of LHRH agonist serum on testosterone levels instead of a fixed cookie cutter schedule currently used by most physicans. Patients usually receive a depot injection of an LHRH agonist based [...]
For many men there comes a time in the treatment process when ADT stops working and the PSA will again begins to rise! Unfortunately, the prostate cancer cells “learn” how to grow without testosterone being present. At this point, we call the cancer androgen independent (AID). When the cancer does become AID, there are still [...]
One of the most commonly discussed adverse side affects from ADT is sexual dysfunction. Due to the decrease in testosterone, most men do experience a decrease in libido and potency. The Prostate Cancer Outcome Study (PCOS) of the SEER program assessed the quality of life outcomes of 431 men who were on ADT (Potosky, AL, [...]
Some men complain that ADT effects their brain. Specifically, they report an inability to remember, an increase of general confusion and trouble focusing on immediate tasks. My personal experience confirms these reports. While on ADT, I often found that I could not recall specifics of conversations or commitments that others claimed I made. I know [...]
It was reported in the October 17th issue of the Journal of the National Cancer Institute by lead author Dr. Henry K. Tsai, from the Harvard Radiation Oncology Program in Boston, that the use of androgen deprivation therapy (ADT) appears to increase the risk of death from cardiovascular disease among men who undergo radical prostatectomy [...]